Cybin (NYSE:CYBN) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Cybin (NYSE:CYBN) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $190.00 price objective on the stock. HC Wainwright also issued estimates for Cybin’s Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.63) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($2.69) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at $4.22 EPS and FY2029 earnings at $9.57 EPS.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Cybin in a research report on Wednesday, July 31st. Canaccord Genuity Group reduced their price target on Cybin from $96.00 to $86.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

Cybin Price Performance

Shares of CYBN stock opened at $10.13 on Monday. The firm has a 50-day moving average of $9.56. The firm has a market cap of $202.52 million, a PE ratio of -1.52 and a beta of 0.38. Cybin has a 52-week low of $6.50 and a 52-week high of $21.66.

Institutional Investors Weigh In On Cybin

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC purchased a new position in shares of Cybin in the second quarter valued at $36,000. AdvisorShares Investments LLC increased its holdings in Cybin by 13.4% during the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company’s stock valued at $494,000 after acquiring an additional 220,403 shares in the last quarter. Rosalind Advisors Inc. raised its position in Cybin by 38.3% during the second quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock worth $5,230,000 after acquiring an additional 5,340,000 shares during the last quarter. RA Capital Management L.P. acquired a new position in Cybin during the first quarter worth about $24,041,000. Finally, Ikarian Capital LLC purchased a new stake in shares of Cybin in the first quarter valued at about $5,770,000. 17.94% of the stock is currently owned by institutional investors and hedge funds.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.